The PP1 inhibitors CD2BP2 and WBP11 [46, 47], acting as CLK1 kinase enhancers, were upregulated in S‐III fractional ESCC and functioned in spliceosome assembly and pre‐mRNA splicing, and knockdown of CD2BP2 and WBP11 significantly inhibited the proliferation of ESCC cells. The gene discussed is CLK1; the disease is esophageal squamous cell carcinoma.